tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Porokeratosis D017499 1 associated lipids
Lentigo D007911 1 associated lipids
Mutism D009155 1 associated lipids
Amyloid Neuropathies D017772 1 associated lipids
Cervical Intraepithelial Neoplasia D018290 1 associated lipids
Migraine with Aura D020325 1 associated lipids
Flaviviridae Infections D018178 1 associated lipids
Idiopathic Interstitial Pneumonias D054988 1 associated lipids
Dysuria D053159 1 associated lipids
Denys-Drash Syndrome D030321 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. 1994 Transplant. Proc. pmid:7527960
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Lye WC Primary tacrolimus-based immunosuppression in renal allograft recipients: a single center experience. 2000 Transplant. Proc. pmid:11119898
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Fukuzawa M and Okada A Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. 1994 Transplant. Proc. pmid:7513483
Warty VS et al. Practical aspects of FK 506 analysis (Pittsburgh experience). 1991 Transplant. Proc. pmid:1721259
Bechstein WO et al. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation. 1996 Transplant. Proc. pmid:8623211
Sher LS et al. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. 1996 Transplant. Proc. pmid:8623212
Yamamoto S et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. 2005 Jan-Feb Transplant. Proc. pmid:15808570
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Ben-Ari Z et al. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. 2003 Transplant. Proc. pmid:12644067
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Lladó L et al. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation. 2002 Transplant. Proc. pmid:11959210
Chang HY et al. Long-term follow-up of arrhythmia characteristics and clinical outcomes in heart transplant patients. 2013 Jan-Feb Transplant. Proc. pmid:23375324
Taibi A et al. Rescue FK506 therapy for acute rejection and early chronic rejection after liver transplantation: report of 14 cases. 1998 Transplant. Proc. pmid:9636571
Melo MJ et al. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study. 2015 Transplant. Proc. pmid:26036484
Müller H et al. Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile. 2008 Transplant. Proc. pmid:18454992
Oishi M et al. A case of hyperkalemic distal renal tubular acidosis secondary to tacrolimus in living donor liver transplantation. 2000 Transplant. Proc. pmid:11120143
Lo CM et al. More effective immunosuppression with the use of FK506 after liver transplantation. 2000 Transplant. Proc. pmid:11120161
Soriano S et al. Single-center experience with initial intravenous dosing of tacrolimus after kidney transplantation. 1999 Transplant. Proc. pmid:10576045
van Hooff JP et al. Dosing and management guidelines for tacrolimus in renal transplant patients. 1999 Transplant. Proc. pmid:10576046
Hu RH et al. Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. 2004 Transplant. Proc. pmid:15518757
McLachlan G et al. Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. 1991 Transplant. Proc. pmid:1721291
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
D'Silva M et al. Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623476
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Goulet O et al. Small bowel transplantation alone or with the liver in children: changes by using FK506. 1998 Transplant. Proc. pmid:9636636
Zhao J et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. 2009 Transplant. Proc. pmid:19545722
Kliem V et al. Long-term results after primary successful FK 506 treatment of steroid- and OKT3-resistant rejection in renal transplant recipients. 1997 Transplant. Proc. pmid:9365627
Fujisaki S et al. Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. 1994 Transplant. Proc. pmid:7518140
Teisseyre J et al. Elevated tacrolimus levels during diarrhea in children after liver transplantation. 2003 Transplant. Proc. pmid:14529919
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Junge G et al. Withdrawal of steroids: a randomized prospective study of prednisone and tacrolimus versus mycophenolate mofetil and tacrolimus in liver transplant recipients with autoimmune hepatitis. 2005 Transplant. Proc. pmid:15919434
Tze WJ et al. FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. 1992 Transplant. Proc. pmid:1376509
Rao PN et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. 1993 Transplant. Proc. pmid:7682366
Armstrong VW et al. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533371
Takai K et al. Delayed graft function after renal transplantation from a non-heart-beating donors. 2003 Transplant. Proc. pmid:12591320
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Jordan ML et al. Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. 1991 Transplant. Proc. pmid:1721323
Mayer AD Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. 2002 Transplant. Proc. pmid:12176452
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Esposito C et al. Effect of calcineurin inhibitors on extracellular matrix turnover in isolated human glomeruli. 2004 Transplant. Proc. pmid:15110634
Wlodarczyk Z et al. Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. 2005 Transplant. Proc. pmid:15919489
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Paul AA et al. CMV retinitis and the use of FK 506. 1991 Transplant. Proc. pmid:1721354
Reyes J et al. Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721355
Pape L et al. Long-term stable glomerular filtration rate achieved with tacrolimus in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12270367
van Hooff JP et al. Benelux experience with a combination of tacrolimus and mycophenolate mofetil: 4-year results. 2002 Transplant. Proc. pmid:12176498
Wu MS et al. Cyclosporine, but not FK 506 and rapamycin, enhances cell proliferation in mouse medullary thick ascending cultured cells. 1998 Transplant. Proc. pmid:9838561
Cheng CY et al. Intervention of Online Percent Coefficient of Variation Reporting System Reduces the Variability of Tacrolimus Trough Concentration in Kidney Transplant Recipients. 2018 Transplant. Proc. pmid:30316366
Meiser BM et al. The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. 1999 Feb-Mar Transplant. Proc. pmid:10083018
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Platz KP et al. Impact of immunosuppression and acute rejection on hepatitis B recurrence. 1997 Feb-Mar Transplant. Proc. pmid:9123107
Reyes J et al. Intestinal transplantation in children: five-year experience. 1996 Transplant. Proc. pmid:8908042
Okano K et al. Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. 1994 Transplant. Proc. pmid:7520635
Thomson AW et al. Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. 1989 Transplant. Proc. pmid:2468203
Hossein-Nia M et al. Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. 1991 Transplant. Proc. pmid:1721388
Citterio F et al. Steroid withdrawal from tacrolimus-based therapy in renal transplant patients. 2002 Transplant. Proc. pmid:12176545
Baran DA et al. Tacrolimus and new onset diabetes mellitus: the effect of steroid weaning. 2002 Transplant. Proc. pmid:12176547
Steinmueller T et al. The effect of cyclosporine vs FK 506 on glucose metabolism. 1999 Feb-Mar Transplant. Proc. pmid:10083504
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. 1999 Feb-Mar Transplant. Proc. pmid:10083507
Fang YH et al. AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report. 2010 Transplant. Proc. pmid:20430219
Ali IH et al. Incidence and risk factors for post-renal transplant diabetes mellitus. 2011 Transplant. Proc. pmid:21440763
Iacona I et al. Mycophenolic acid in combination with FK 506: a pharmacokinetic study in piglets after small-bowel transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123489
Ayar Y et al. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience. 2017 Transplant. Proc. pmid:28219583
Batten P et al. Effect of cyclosporine A and FK 506 on human T cell responses to xenogeneic and allogeneic endothelium: relative resistance of T cell/porcine endothelial interactions. 1997 Feb-Mar Transplant. Proc. pmid:9123582
Langer RM et al. De novo tumors after kidney transplantation: the Budapest experience. 2003 Transplant. Proc. pmid:12826170
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
Markus PM et al. The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. 1991 Transplant. Proc. pmid:1721418
Yuzawa K et al. Topical immunosuppression in skin grafting with FK 506 ointment. 1996 Transplant. Proc. pmid:8658707
White SA et al. Randomized trial comparing neoral and tacrolimus immunousuppression for recipients of renal transplants procured from different donor groups. 2000 Transplant. Proc. pmid:10812132
Calne RY The development of immunosuppression: the rapamycin milestone. 2003 Transplant. Proc. pmid:12742463
Beckebaum S et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. 2004 Transplant. Proc. pmid:15621120
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Woeste G et al. Tacrolimus/mycophenolate mofetil vs cyclosporine A/Azathioprine after simultaneous pancreas and kidney transplantation: five-year results of a randomized study. 2002 Transplant. Proc. pmid:12176629
Shishido S et al. Pharmacokinetics of tacrolimus in pediatric renal transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267193
Atillasoy E et al. Cholesterol levels long-term after liver transplant. 1998 Transplant. Proc. pmid:9723387
Quijano Y et al. Tolerance: a study in long-term surviving animals after small bowel transplantation. 1998 Transplant. Proc. pmid:9745494
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Duzova A et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. 2003 Transplant. Proc. pmid:14697926
Ybarra J et al. Reflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with tacrolimus. 2003 Transplant. Proc. pmid:14697943
Yumiba T et al. Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. 1995 Transplant. Proc. pmid:7540780
Nikolaidis NL et al. Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. 1991 Transplant. Proc. pmid:1721450
Abu-Elmagd K et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. 1991 Transplant. Proc. pmid:1721451
Ochiai T et al. Studies on FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450414
Kiji T et al. Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. 2004 Transplant. Proc. pmid:15561265
Immunosuppression: FK506. 1988 Transplant. Proc. pmid:2450415
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
Mehra MR et al. A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267438
Yoshimura N et al. Development of a macromolecular prodrug of FK 506: III: In vivo disposition of FK 506-dextran conjugate. 1998 Transplant. Proc. pmid:9636415
Fung JJ et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. 1991 Transplant. Proc. pmid:1703682
Boggi U et al. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation. 2001 Nov-Dec Transplant. Proc. pmid:11750373
Lawen J et al. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. 2001 Nov-Dec Transplant. Proc. pmid:11750382
Kliem V et al. Tacrolimus for steroid- and OKT3-resistant rejection in kidney recipients. 1998 Transplant. Proc. pmid:9636509
Copley JB et al. Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts. 1998 Transplant. Proc. pmid:9636510